Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-12-17 Purchase |
2024-12-18 08:27 am |
NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chairman and Chief Scientist 10% Owner |
40,000 | $1.17 | $46,800 | 1,516,834 (Indirect Direct) |
View |
| 2023-08-30 Purchase |
2023-09-11 09:19 am |
NRX Pharmaceuticals Inc. | NRXP | Gorovitz Aaron Director |
35,000 | $0.3199 | $11,197 | 105,000 (Indirect) |
View |
| 2023-08-30 Purchase |
2023-09-11 09:15 am |
NRX Pharmaceuticals Inc. | NRXP | Hurvitz Chaim Director |
70,000 | $0.2875 | $20,125 | 2,214,793 (Indirect Direct) |
View |
| 2023-08-23 Purchase |
2023-08-24 12:14 pm |
NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Scientist 10% Owner |
100,000 | $0.33 | $33,000 | 14,768,329 (Indirect Direct) |
View |
| 2023-08-22 Purchase |
2023-08-23 09:24 am |
NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Scientist 10% Owner |
200,000 | $0.322 | $64,400 | 14,668,329 (Indirect Direct) |
View |
| 2022-12-16 Purchase |
2022-12-19 07:14 am |
NRX Pharmaceuticals Inc. | NRXP | Willard Stephen H CHIEF EXECUTIVE OFFICER |
50,000 | $1.17 | $58,500 | 50,000 (Direct) |
View |
| 2022-12-16 Purchase |
2022-12-19 07:09 am |
NRX Pharmaceuticals Inc. | NRXP | VAN VOORHEES SETH CHIEF FINANCIAL OFFICER |
30,000 | $1.1 | $33,000 | 46,337 (Direct) |
View |
| 2022-11-25 Purchase(A) |
2022-12-19 07:08 am |
NRX Pharmaceuticals Inc. | NRXP | VAN VOORHEES SETH CHIEF FINANCIAL OFFICER |
16,337 | $1.115 | $18,215 | 16,337 (Direct) |
View |
| 2022-12-07 Sale |
2022-12-09 4:33 pm |
NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Director 10% Owner |
400,000 | $1 | $400,000 | 14,468,329 (Indirect Direct) |
View |
| 2022-11-29 Sale |
2022-12-01 7:29 pm |
NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner |
22,171 | $1.5043 | $33,352 | 9,634,793 (Indirect) |
View |
| 2022-11-28 Purchase |
2022-11-29 07:00 am |
NRX Pharmaceuticals Inc. | NRXP | Flynn Patrick John Director |
11,750 | $1.2479 | $14,663 | 41,959 (Indirect Direct) |
View |
| 2022-11-25 Purchase |
2022-11-28 07:42 am |
NRX Pharmaceuticals Inc. | NRXP | VAN VOORHEES SETH CHIEF FINANCIAL OFFICER |
16,337 | $1.115 | $18,215 | 16,377 (Indirect) |
View |
| 2022-11-16 Purchase(A) |
2022-11-23 4:09 pm |
NRX Pharmaceuticals Inc. | NRXP | Hurvitz Chaim Director |
500,000 | $1.0298 | $514,905 | 500,000 (Direct) |
View |
| 2022-11-16 Purchase |
2022-11-21 5:58 pm |
NRX Pharmaceuticals Inc. | NRXP | Hurvitz Chaim Director |
500,000 | $1.0298 | $514,905 | 2,525,876 (Indirect Direct) |
View |
| 2022-11-16 Sale |
2022-11-18 7:05 pm |
NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner |
166,737 | $1.0264 | $171,138 | 9,656,964 (Indirect) |
View |
| 2022-11-11 Sale |
2022-11-15 7:40 pm |
NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner |
49,200 | $1.0063 | $49,510 | 9,823,701 (Indirect) |
View |
| 2022-07-29 Sale |
2022-08-02 5:43 pm |
NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner |
784,063 | $1.0094 | $791,433 | 9,872,901 (Indirect) |
View |
| 2022-06-03 Sale |
2022-06-07 8:11 pm |
NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner |
445,712 | $0.68185 | $303,910 | 12,656,964 (Indirect) |
View |
| 2022-06-01 Purchase(A) |
2022-06-02 09:46 am |
NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Scientist 10% Owner |
100,000 | $0.58 | $58,000 | 14,868,329 (Indirect Direct) |
View |
| 2022-06-01 Purchase |
2022-06-02 08:55 am |
NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Scientist 10% Owner |
100,000 | $58 | $5,800,000 | 14,868,329 (Indirect Direct) |
View |
| 2021-08-23 Sale |
2021-11-02 4:05 pm |
NRX Pharmaceuticals Inc. | NRXP | Daigneault Alessandra General Counsel & Secretary |
33,715 | $13.11 | $442,004 | 308,591 (Direct) |
View |
| 2021-09-15 Sale |
2021-11-02 4:04 pm |
NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Chief Comm. & Patient Officer |
40,000 | $11.76 | $470,400 | 307,200 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-07 Option Award |
2025-02-11 5:00 pm |
N/A 2035-02-07 |
NRX Pharmaceuticals Inc. | NRXP | ABRAMS MICHAEL S Chief Financial Officer |
50,000 | $0 | 50,000 (Direct) |
View |
Ownership |
2024-06-26 7:37 pm |
N/A 2027-06-14 |
NRX Pharmaceuticals Inc. | NRXP | McBride Dennis Director |
0 | $0 | 6,320 (Direct) |
View |
| 2022-12-14 Ownership |
2023-02-14 5:14 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Director 10% Owner |
300,000 | $0 | 14,468,329 (Indirect) |
View |
| 2022-10-21 Option Award |
2022-11-22 5:46 pm |
N/A 2032-10-21 |
NRX Pharmaceuticals Inc. | NRXP | Gorovitz Aaron Director |
162,660 | $0 | 162,660 (Direct) |
View |
| 2022-10-21 Option Award |
2022-11-22 5:45 pm |
N/A 2032-10-21 |
NRX Pharmaceuticals Inc. | NRXP | Glied Sharon Director |
162,660 | $0 | 228,097 (Direct) |
View |
| 2022-10-21 Option Award |
2022-11-22 5:44 pm |
N/A 2032-10-21 |
NRX Pharmaceuticals Inc. | NRXP | Flynn Patrick John Director |
162,660 | $0 | 162,660 (Direct) |
View |
| 2022-10-21 Option Award |
2022-11-21 5:58 pm |
N/A 2032-10-21 |
NRX Pharmaceuticals Inc. | NRXP | Hurvitz Chaim Director |
162,660 | $0 | 2,525,876 (Direct) |
View |
Ownership |
2022-07-22 4:27 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | Willard Stephen H Chief Executive Officer |
0 | $0 | 1,000,000 (Direct) |
View |
| 2022-07-01 Gift |
2022-07-05 5:06 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner |
2,000,000 | $0 | 10,656,964 (Indirect) |
View |
Ownership |
2022-06-29 6:14 pm |
2023-06-13 2032-06-12 |
NRX Pharmaceuticals Inc. | NRXP | VAN VOORHEES SETH Chief Financial Officer |
0 | $0 | 325,000 (Direct) |
View |
Ownership |
2022-03-24 6:25 pm |
2023-03-15 2032-03-14 |
NRX Pharmaceuticals Inc. | NRXP | Strassberg Ira S Chief Financial Officer |
0 | $0 | 425,000 (Direct) |
View |
| 2022-03-08 Option Award |
2022-03-10 4:04 pm |
N/A 2032-03-08 |
NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Interim CEO |
100,000 | $2.61 | 347,200 (Direct) |
View |
| 2021-08-26 Conversion |
2021-11-02 4:07 pm |
N/A 2028-01-04 |
NRX Pharmaceuticals Inc. | NRXP | McMaster Herbert Raymond Director |
28,724 | $2.22 | 45,086 (Direct) |
View |
| 2021-08-26 Option Award |
2021-11-02 4:07 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | McMaster Herbert Raymond Director |
10,424 | $0 | 45,086 (Direct) |
View |
| 2021-08-26 Exercise |
2021-11-02 4:07 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | McMaster Herbert Raymond Director |
18,300 | $2.22 | 45,086 (Direct) |
View |
| 2021-07-16 Gift |
2021-11-02 4:06 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner |
434,594 | $0 | 13,102,676 (Indirect) |
View |
| 2021-08-19 Option Award |
2021-11-02 4:05 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | Daigneault Alessandra General Counsel & Secretary |
33,603 | $0 | 308,591 (Direct) |
View |
| 2021-08-19 Conversion |
2021-11-02 4:05 pm |
N/A 2030-09-01 |
NRX Pharmaceuticals Inc. | NRXP | Daigneault Alessandra General Counsel & Secretary |
92,582 | $3.07 | 308,591 (Direct) |
View |
| 2021-08-19 Exercise |
2021-11-02 4:05 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | Daigneault Alessandra General Counsel & Secretary |
58,979 | $3.07 | 308,591 (Direct) |
View |
| 2021-08-16 Option Award |
2021-11-02 4:04 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Chief Comm. & Patient Officer |
36,290 | $0 | 307,200 (Direct) |
View |
| 2021-08-16 Exercise |
2021-11-02 4:04 pm |
N/A N/A |
NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Chief Comm. & Patient Officer |
63,710 | $0.2 | 307,200 (Direct) |
View |
| 2021-08-16 Conversion |
2021-11-02 4:04 pm |
N/A 2026-03-01 |
NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Chief Comm. & Patient Officer |
100,000 | $0.2 | 307,200 (Direct) |
View |
Ownership |
2021-11-02 4:03 pm |
N/A 2028-01-04 |
NRX Pharmaceuticals Inc. | NRXP | McMaster Herbert Raymond Director |
0 | $0 | 48,931 (Direct) |
View |
| 2021-05-24 Option Award |
2021-06-10 6:48 pm |
N/A 2028-04-01 |
NRX Pharmaceuticals Inc. | NRXP | Troy Daniel Director |
108,530 | $0 | 108,530 (Direct) |
View |